{"id":"W4415315812","doi":"10.1016/j.jiac.2025.102834","title":"Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study","year":2025,"lang":"en","type":"article","venue":"Journal of Infection and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Pharmaceuticals; ViiV Healthcare","keywords":"Rilpivirine; Tenofovir alafenamide; Adverse effect; Regimen; Randomized controlled trial; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001565507,0.000215625,0.0009329233,0.0006269367,0.00006263496,0.00004274094,0.0000642559,0.00005131935,0.00001021264],"category_scores_gemma":[0.0001522684,0.0001171943,0.000124322,0.0004896238,0.00003091537,0.0001832827,0.000009784605,0.0003222479,3.453804e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001391544,"about_ca_system_score_gemma":0.0001089721,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003435025,"about_ca_topic_score_gemma":0.001561154,"domain_scores_codex":[0.9984351,0.0002297968,0.000702732,0.0001604756,0.0002857537,0.0001861902],"domain_scores_gemma":[0.9990455,0.0003170317,0.000320472,0.0001373606,0.0001129865,0.00006664731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07260785,0.002483145,0.8557138,0.00002608111,0.0006376699,0.0001125053,0.01024732,0.0000471643,0.0008418012,0.00001281069,0.00001590474,0.05725399],"study_design_scores_gemma":[0.4443306,0.002639418,0.5450423,0.0004168031,0.0003613499,0.00004828699,0.004656963,0.0003635328,0.001722507,0.00003860021,0.0002073823,0.0001722386],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947053,0.0000849893,0.001849947,0.002093197,0.0001157937,0.0009062859,5.022342e-7,0.00001127685,0.0002327049],"genre_scores_gemma":[0.9984024,0.0001630962,0.0007832132,0.0002652601,0.00003448589,0.00001821784,0.000001781076,0.00001522929,0.0003163115],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3717227,"threshold_uncertainty_score":0.4779046,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01484259345914538,"score_gpt":0.334879915434438,"score_spread":0.3200373219752926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}